TLIS News and Press, Talis Biomedical Corporation From 11/15/21

Talis Biomedical Corporation (NASDAQ:TLIS) posted better-than-expected revenue for Q3 2021 and announced its latest leadership change with the earnings release. The company has appointed Brian Blaser to President, Chief Executive Officer, and Director, replacing the interim CEO Kim Popov...

Talis Biomedical (NASDAQ:TLIS): GAAP EPS of -$1.49 beats by $0.18. Revenue of $218M (+2219.1% Y/Y) beats by $216.54M. Press Release For further details see: Talis Biomedical EPS beats by $0.18, beats on revenue

MENLO PARK, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today reported financial re...

Veteran executive previously led Abbott's global diagnostics organization Kim Popovits, interim chief executive officer, to resume role as Director on the Board of Talis MENLO PARK, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a co...

Talis Biomedical (NASDAQ:TLIS) announces that the U.S. FDA has granted Emergency Use Authorization (EUA) for its Talis One COVID-19 Test System - a nucleic acid amplification test (NAAT). Shares up more than 8% premarket. The test runs on an integrated system that includes...

Authorized for use in a variety of healthcare and congregate settings, Talis One™ enables lab-quality results without the wait to detect or rule out COVID-19 in less than 30 minutes Talis One’s robust dual gene target design optimizes test sensitivity and inclusivity...

MENLO PARK, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation ("TLIS"), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced that it will release financial results for the third quarter aft...

Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...

Gainers: Cellect Biotechnology (NASDAQ:APOP) +24%, Keros Therapeutics (NASDAQ:KROS) +24%, Gossamer Bio (NASDAQ:GOSS) +17%, Seelos Therapeutics (NASDAQ:SEEL) +16%, DiaMedica Therapeutics (NASDAQ:DMAC) +9%. Losers: ASLAN Pharmaceuticals (NASDAQ:ASLN)...

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Talis Biomedical Corporation (“Talis” or the “Company”) (NASDAQ: TLIS) on behalf of Talis stockholders. Our investigation conce...